Literature DB >> 1689993

Therapeutic effect of isovolemic hemodilution with dextran 60 on the impairment of pancreatic microcirculation in acute biliary pancreatitis.

E Klar1, C Herfarth, K Messmer.   

Abstract

Dextran of different molecular weight (Dx 40, Dx 60/70) has often been evaluated as adjunct treatment of experimental acute pancreatitis. A beneficial effect has been documented by a decrease in its lethality. However, the mechanism of action is poorly understood. A specific effect on the pancreatic microcirculation generally has not been documented and differentiation from unspecific improvement of pancreatic blood flow due to volume expansion has been difficult. This investigation was designed to quantify the effect of dextran on the impairment of pancreatic microcirculation during acute biliary pancreatitis by means of intravital microscopy. Dextran 60 (Dx 60, molecular weight 60,000) was chosen in light of the increase in vascular permeability in the early stage of pancreatitis as demonstrated previously in the same model. Isovolemic hemodilution, i.e., exchange of whole blood for Dx 60 was used as a mode of administration to achieve instantaneous onset of therapy without changes in intravascular volume. In the control group a progressive reduction of pancreatic capillary perfusion commenced 30 minutes after induction of acute pancreatitis, resulting in cessation of nutritive tissue perfusion after 3 hours. In the animals subjected to hemodilution, stabilization of the pancreatic microcirculation was accomplished throughout the observation period of 6 hours. Because volume-related effects could be excluded by the protocol and by monitoring central venous pressure and hematocrit, a specific effect of hemodilution with DX 60 on the pancreatic microcirculation is indicated by our results.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689993      PMCID: PMC1358441          DOI: 10.1097/00000658-199003000-00006

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  45 in total

1.  Effect of proteolytic enzymes upon pancreatic blood vessels.

Authors:  M C ANDERSON; J J BERGAN
Journal:  Surg Forum       Date:  1962

2.  [STUDIES FOR THE EVALUATION OF COLLOIDAL VOLUME SUBSTITUTION].

Authors:  F W AHNEFELD; M HALMAGYI; K UBERLA
Journal:  Anaesthesist       Date:  1965-05       Impact factor: 1.041

3.  Rheomacrodex--a new dextran solution for rheological treatment of impaired capillary flow.

Authors:  L E GELIN; B INGELMAN
Journal:  Acta Chir Scand       Date:  1961-11

4.  Treatment of acute pancreatitis with albumin and whole blood.

Authors:  D W ELLIOTT
Journal:  AMA Arch Surg       Date:  1957-10

5.  Gradations of pancreatitis, edematous, through hemorrhagic, experimentally produced by controlled injection of microspheres into blood vessels in dogs.

Authors:  R B PFEFFER; A LAZZARINI-ROBERTSON; D SAFADI; G MIXTER; C F SECOY; J W HINTON
Journal:  Surgery       Date:  1962-06       Impact factor: 3.982

6.  The effect of the intravenous administration of dextran on cardiac output and other circulatory dynamics.

Authors:  A C WITHAM; J W FLEMING; W L BLOOM
Journal:  J Clin Invest       Date:  1951-09       Impact factor: 14.808

7.  Microvascular hemodynamics during systemic hemodilution and hemoconcentration.

Authors:  H H Lipowsky; J C Firrell
Journal:  Am J Physiol       Date:  1986-06

Review 8.  Acceptable hematocrit levels in surgical patients.

Authors:  K F Messmer
Journal:  World J Surg       Date:  1987-02       Impact factor: 3.352

9.  Studies on pancreatitis. IV. The pathogenesis of bile pancreatitis.

Authors:  A THAL
Journal:  Surg Forum       Date:  1955

Review 10.  Hemodynamic function in acute pancreatitis.

Authors:  J W Horton; C A Burnweit
Journal:  Surgery       Date:  1988-05       Impact factor: 3.982

View more
  18 in total

1.  Advances in endoscopy: current developments in diagnostic and therapeutic endoscopy.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-01

2.  Admission hematocrit: a simple, useful and early predictor of severe pancreatitis.

Authors:  S Ian Gan; Joseph Romagnuolo
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 3.  Fluid resuscitation in acute pancreatitis.

Authors:  Aakash Aggarwal; Manish Manrai; Rakesh Kochhar
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

4.  Isovolemic hemodilution with dextran 60 as treatment of pancreatic ischemia in acute pancreatitis. Clinical practicability of an experimental concept.

Authors:  E Klar; T Foitzik; H Buhr; K Messmer; C Herfarth
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

5.  Intravenous contrast medium does not increase the severity of acute necrotizing pancreatitis in the opossum.

Authors:  A M Kaiser; T Grady; D Gerdes; M Saluja; M L Steer
Journal:  Dig Dis Sci       Date:  1995-07       Impact factor: 3.199

Review 6.  Microvasculature of the pancreas. Relation to pancreatitis.

Authors:  D E Bockman
Journal:  Int J Pancreatol       Date:  1992-08

7.  Dexamethasone and dextran 40 treatment of 32 patients with severe acute pancreatitis.

Authors:  Zi-Fa Wang; Chang Liu; Yi Lu; Rui Dong; Jun Xu; Liang Yu; Ying-Min Yao; Qing-Guang Liu; Cheng-En Pan
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

8.  Systemic intravenous infusion of bovine hemoglobin significantly reduces microcirculatory dysfunction in experimentally induced pancreatitis in the rat.

Authors:  Tim Strate; Oliver Mann; Helge Kleinhans; Claus Schneider; Wolfram T Knoefel; Emre Yekebas; Thomas Standl; Christian Bloechle; Jakob R Izbicki
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

Review 9.  [Acute pancreatitis].

Authors:  S Wagner; H Lübbers; R Mahlke; C H Müller; P G Lankisch
Journal:  Internist (Berl)       Date:  2003-05       Impact factor: 0.743

10.  The role of the intestine in the pathophysiology and management of severe acute pancreatitis.

Authors:  R S Flint; J A Windsor
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.